Trial Profile
A Phase II Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Alveolar soft part sarcoma; Chordoma; Haemangioendothelioma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Osteosarcoma; Sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 18 Oct 2023 Planned End Date changed from 31 Dec 2023 to 27 Dec 2024.
- 18 Oct 2023 Planned primary completion date changed from 31 Dec 2023 to 27 Dec 2024.
- 07 Dec 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.